Satellos Reports the First Patient Dosing with SAT-3247 in P-I Trial for Duchenne Muscular Dystrophy
Shots:
- Satellos has dosed the first patient with SAT-3247 (oral) under its P-I study for the treatment of duchenne muscular dystrophy
- The part 1 of P-I study involves healthy subjects (n=72) to evaluate the safety & PK across 5 single-ascending dose (SAD) cohorts & 4 multiple-ascending dose (MAD) cohorts with 1 food effect cohort and part 2 (anticipated in Q1’25) involves DMD adult patients (n=10) for a 28-day evaluation of safety & PK/PD. Initial safety and PK data is planned in Q4’24
- SAT-3247 is a small molecule for restore skeletal muscle in Duchenne muscular dystrophy (DMD) and other degenerative conditions. It is intended to treat DMD irrespective of dystrophin and exon mutation status
Ref: Sarepta Therapeutics | Image: Sarepta Therapeutics
Related News:- Sarepta Therapeutics’ Elevidys Gains the US FDA’s Label Expansion Approval for Duchenne Muscular Dystrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
